Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study

Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study

Bortezomib is a pivotal drug for the management of multiple myeloma. However, bortezomib is a neurotoxic anticancer drug responsible for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with psychological distress and a decrease of health-related quality of life (HRQoL), but lit...

Full description

Bibliographic Details
Main Authors: Marie Selvy, Nicolas Kerckhove, Bruno Pereira, Fantine Barreau, Daniel Nguyen, Jérôme Busserolles, Fabrice Giraudet, Aurélie Cabrespine, Carine Chaleteix, Martin Soubrier, Jacques-Olivier Bay, Richard Lemal, David Balayssac
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
bortezomib
multiple myeloma
chemotherapy-induced peripheral neuropathy
neuropathic pain
health-related quality of life
anxiety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.637593/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.637593/full

Similar Items